JP2012509295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012509295A5 JP2012509295A5 JP2011536843A JP2011536843A JP2012509295A5 JP 2012509295 A5 JP2012509295 A5 JP 2012509295A5 JP 2011536843 A JP2011536843 A JP 2011536843A JP 2011536843 A JP2011536843 A JP 2011536843A JP 2012509295 A5 JP2012509295 A5 JP 2012509295A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- amyloid
- seq
- binds
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 20
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 20
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 3
- 230000004807 localization Effects 0.000 claims description 3
- 238000011002 quantification Methods 0.000 claims description 3
- 150000008574 D-amino acids Chemical class 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 230000006806 disease prevention Effects 0.000 claims 3
- 150000008575 L-amino acids Chemical class 0.000 claims 2
- 210000004102 animal cell Anatomy 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 210000004754 hybrid cell Anatomy 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102008037564.0 | 2008-11-19 | ||
| DE102008037564A DE102008037564A1 (de) | 2008-11-19 | 2008-11-19 | Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden |
| PCT/EP2009/065308 WO2010057882A2 (de) | 2008-11-19 | 2009-11-17 | Zusammensetzung zur herstellung von anti-amyloid beta-peptid-antikörpern mit d-peptiden |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012509295A JP2012509295A (ja) | 2012-04-19 |
| JP2012509295A5 true JP2012509295A5 (OSRAM) | 2013-01-17 |
| JP6029280B2 JP6029280B2 (ja) | 2016-11-24 |
Family
ID=41572521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011536843A Expired - Fee Related JP6029280B2 (ja) | 2008-11-19 | 2009-11-17 | D−ペプチドを有する抗−アミロイドβ−ペプチド抗体を製造するための組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9051364B2 (OSRAM) |
| EP (1) | EP2356144B1 (OSRAM) |
| JP (1) | JP6029280B2 (OSRAM) |
| CN (1) | CN102224168B (OSRAM) |
| DE (1) | DE102008037564A1 (OSRAM) |
| WO (1) | WO2010057882A2 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010017130B4 (de) * | 2010-05-28 | 2018-11-29 | Forschungszentrum Jülich GmbH | Hybrid-Verbindung, deren Verwendung und Verfahren zu deren Herstellung |
| AU2012274910B2 (en) | 2011-06-24 | 2017-05-11 | Nono, Inc. | Combination therapy with PSD-95 inhibitor for ischemia |
| US9241970B2 (en) * | 2011-12-13 | 2016-01-26 | Nono Inc. | Therapy for subarachnoid hemorrhage and ischemia |
| WO2013150127A2 (de) | 2012-04-05 | 2013-10-10 | Forschungszentrum Jülich GmbH | Polymere, enthaltend multivalente amyloid-beta-bindende d-peptide und deren verwendung |
| PL3260865T3 (pl) * | 2012-04-05 | 2023-04-11 | Priavoid Gmbh | Sposób obróbki krwi, produktów krwiopochodnych i narządów |
| DE102012108598A1 (de) * | 2012-09-14 | 2014-04-10 | Forschungszentrum Jülich GmbH | Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung |
| DE102012102998B4 (de) * | 2012-04-05 | 2013-12-05 | Forschungszentrum Jülich GmbH | Polymere, enthaltend multivalente Amyloid-Beta-bindende D-Peptide und deren Verwendung |
| DE102014003262A1 (de) | 2014-03-12 | 2015-09-17 | Forschungszentrum Jülich GmbH | Amyloid-Beta-bindende Peptide und deren Verwendung für die Therapie und die Diagnose der Alzheimerschen Demenz |
| DE102013016002A1 (de) * | 2013-09-26 | 2015-03-26 | Forschungszentrum Jülich GmbH | Zyklische, Amyloid-Beta-bindende Peptide und deren Verwendung |
| EP3747454B9 (de) | 2013-09-26 | 2023-10-04 | Priavoid GmbH | Amyloid-beta-bindende peptide und diese peptide zur verwendung für die therapie und die diagnose der alzheimerschen demenz |
| DE102015003676A1 (de) * | 2015-03-20 | 2016-09-22 | Forschungszentrum Jülich GmbH Fachbereich Patente | Spezifisch A-Beta Spezies bindende Peptide für die Therapie und/oder die Diagnose der Alzheimerschen Demenz |
| JP7368856B2 (ja) | 2017-07-25 | 2023-10-25 | トゥルーバインディング,インコーポレイテッド | Tim-3とそのリガンドとの相互作用の遮断によるがん治療 |
| CN116063505B (zh) | 2019-01-30 | 2024-05-03 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| US12281166B2 (en) | 2020-05-26 | 2025-04-22 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4116072B2 (ja) * | 1992-08-27 | 2008-07-09 | バイオクローンズ(プロプライエタリー)リミテッド | 逆向き、鏡像体および逆向き鏡像体合成ペプチド類似物 |
| US6277826B1 (en) * | 1996-08-27 | 2001-08-21 | Praecis Pharmaceuticals, Inc. | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
| BR0008738A (pt) * | 1999-03-04 | 2001-12-26 | Praecis Pharm Inc | Moduladores de agregação de peptìdeobeta-amilóide compreendendo d-aminoácidos |
| US6849714B1 (en) * | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| DE10117281A1 (de) * | 2001-04-06 | 2002-10-24 | Inst Molekulare Biotechnologie | Peptid zur Diagnose und Therapie der Alzheimer-Demenz |
| US6906169B2 (en) | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
| US20050026165A1 (en) * | 2001-05-31 | 2005-02-03 | Cindy Orser | Detection of conformationally altered proteins and prions |
| AR047062A1 (es) * | 2003-12-17 | 2006-01-04 | Wyeth Corp | Conjugados portadores de peptidos inmunogenicos a beta y metodos para producirlos |
-
2008
- 2008-11-19 DE DE102008037564A patent/DE102008037564A1/de not_active Withdrawn
-
2009
- 2009-11-17 JP JP2011536843A patent/JP6029280B2/ja not_active Expired - Fee Related
- 2009-11-17 CN CN200980146026.4A patent/CN102224168B/zh not_active Expired - Fee Related
- 2009-11-17 WO PCT/EP2009/065308 patent/WO2010057882A2/de not_active Ceased
- 2009-11-17 EP EP09774854.5A patent/EP2356144B1/de not_active Not-in-force
- 2009-11-17 US US13/129,579 patent/US9051364B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012509295A5 (OSRAM) | ||
| Flyak et al. | Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2–MPER region | |
| Sangesland et al. | Allelic polymorphism controls autoreactivity and vaccine elicitation of human broadly neutralizing antibodies against influenza virus | |
| JP2010514805A5 (OSRAM) | ||
| CN102224168B (zh) | 用于生产抗淀粉状蛋白β肽抗体的含有D-肽的组合物 | |
| JP2014523742A5 (OSRAM) | ||
| JP2011528561A5 (OSRAM) | ||
| JP2002528140A5 (OSRAM) | ||
| JP2023525518A (ja) | 新規アンキリンリピート結合タンパク質とその用途 | |
| RU2013106270A (ru) | Моноклональное антитело против addl и его применения | |
| JP2013542914A5 (OSRAM) | ||
| CN102498217A (zh) | Hpv的e6蛋白的特异性抗体及其应用 | |
| Zhang et al. | Multiple proteins of White spot syndrome virus involved in recognition of β-integrin | |
| JP2013505938A5 (OSRAM) | ||
| EP3992205A1 (en) | Sars coronavirus-2 spike protein binding compounds | |
| JP2012523221A5 (OSRAM) | ||
| CN103833830B (zh) | 柯萨奇病毒a16型的保守中和表位多肽及其用途 | |
| JP2018529630A (ja) | 自閉症を診断および治療するための抗原性ペプチドおよびその使用 | |
| CA3214262A1 (en) | Pharmaceutical composition for ameliorating acute lung injury and acute worsening of pulmonary fibrosis | |
| JP2009525741A5 (ja) | HERV−W干渉群に属するウィルスの包膜とhASCT受容体との間の相互作用に必要なペプチド領域からなるペプチド | |
| RU2014102721A (ru) | Способ получения агента, связывающегося с препро-вазопрессином или с его фрагментами | |
| CN104277110A (zh) | 一种针对人Tudor-SN蛋白T73位点的应激磷酸化抗体制备方法 | |
| JP2012503634A5 (OSRAM) | ||
| JP2023145633A5 (OSRAM) | ||
| JP2008522632A5 (OSRAM) |